Disease · MONDO_0006014

vulvovaginal candidiasis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. vulvovaginal candidiasis. Diseases, record MONDO_0006014. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006014

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: vulvovaginal candidiasis; Open Targets
Open Targets ID: MONDO_0006014; Open Targets
Other names: Candidal vulvovaginitis (disorder), Candidal vulvovaginitis NOS (disorder), Candidiasis, Vulvovaginal, candidal vulvovaginitis, candidal: [vulvovaginitis NOS] or [cervix], candidal: cervix, candidiasis of vulva and vagina, monilial vulvovaginitis, vaginal candidiasis; Open Targets
Disease Ontology: DOID:2272; Disease Ontology
MeSH: D002181; MeSH
NCI Thesaurus: C2914; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 30 drugs, from DailyMed, FDA and TTD; Open Targets

Drugs30

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
FLUCONAZOLE	CHEMBL106	Small molecule	Approval	DailyMed	16	14	14	Drugs and targets
OTESECONAZOLE	CHEMBL3311228	Small molecule	Approval	FDA and TTD	8	6	6	Drugs and targets
IBREXAFUNGERP	CHEMBL4297513	Small molecule	Approval	TTD	4	3	3	Drugs and targets
IBREXAFUNGERP CITRATE	CHEMBL4298168	Small molecule	Approval	FDA	1	0	0	Drugs and targets
CLOTRIMAZOLE	CHEMBL104	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
BORIC ACID	CHEMBL42403	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
KETOCONAZOLE	CHEMBL157101	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
LACTULOSE	CHEMBL296306	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TERCONAZOLE	CHEMBL1714574	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TINIDAZOLE	CHEMBL1220	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 30

See all 30 drugs

Targets10

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SCN10A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6329	Drugs and targets
SCN5A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6331	Drugs and targets
SCN7A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6332	Drugs and targets
SCN8A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6334	Drugs and targets
SCN9A	Sodium channel alpha subunit	1	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6335	Drugs and targets

Trials43

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01039584	A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations	Not applicable	611	2013-01-21	Vulvovaginal Candidiasis	BUTOCONAZOLE NITRATE	Its record names the disease	ClinicalTrials.gov
NCT00803738	Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis	Not applicable	572	2013-02-20	Vulvovaginal Candidiasis	TERCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03987620	Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis	Phase 3	455	2021-09-08	Candida Vulvovaginitis	IBREXAFUNGERP	Its record names the disease	ClinicalTrials.gov
NCT03562156	A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)	Phase 3	438	2022-01-13	Recurrent Vulvovaginal Candidiasis	OTESECONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03561701	A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)	Phase 3	425	2021-12-20	Recurrent Vulvovaginal Candidiasis	OTESECONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT02267382	A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)	Phase 2	254	2019-10-04	Recurrent Vulvovaginal Candidiasis	OTESECONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01144286	Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment	Phase 2	229	2013-10-09	Vulvovaginal Candidiasis	ARASERTACONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03840616	Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections	Phase 3	219	2022-02-04	Recurrent Vulvovaginal Candidiasis	FLUCONAZOLE, OTESECONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01806623	The Study Of Fluconazole For Vulvovaginal Candidiasis	Phase 3	157	2014-12-03	Vulvovaginal Candidiasis	FLUCONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT05399641	Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis	Phase 3	150	2024-07-10	Vulvovaginal Candidiasis	IBREXAFUNGERP	Its record names the disease	ClinicalTrials.gov

1 to 10 of 43

See all 43 trials

Comparisons in its trials10

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Terconazole Vaginal Suppositories, 80 mg - Perrigo vs Terazol 3 - Terconazole Vaginal Suppositories 80 mg: serious adverse events	0 of 282	1 of 275	557	NCT00803738	Trial comparisons
Ibrexafungerp (SCY-078) vs Placebo: deaths from any cause	0 of 298	0 of 151	449	NCT03987620	Trial comparisons
Ibrexafungerp (SCY-078) vs Placebo: serious adverse events	1 of 298	1 of 151	449	NCT03987620	Trial comparisons
Oteseconazole (VT-1161) vs Placebo: deaths from any cause	0 of 217	0 of 110	327	NCT03561701	Trial comparisons
Oteseconazole (VT-1161) vs Placebo: serious adverse events	7 of 217	5 of 110	327	NCT03561701	Trial comparisons
Oteseconazole (VT-1161) vs Placebo: deaths from any cause	0 of 217	0 of 109	326	NCT03562156	Trial comparisons
Oteseconazole (VT-1161) vs Placebo: serious adverse events	3 of 217	3 of 109	326	NCT03562156	Trial comparisons
Terconazole Vaginal Suppositories, 80 mg - Perrigo vs Terazol 3 - Terconazole Vaginal Suppositories 80 mg: Proportion of Subjects With Clinical Cure	117 of 153	101 of 147	300	NCT00803738	Trial comparisons
Terconazole Vaginal Suppositories, 80 mg - Perrigo vs Terazol 3 - Terconazole Vaginal Suppositories 80 mg: Proportion of Subjects With Mycological Cure	127 of 153	117 of 147	300	NCT00803738	Trial comparisons
Terconazole Vaginal Suppositories, 80 mg - Perrigo vs Terazol 3 - Terconazole Vaginal Suppositories 80 mg: Proportion of Subjects in Each Treatment Group With Therapeutic Cure	105 of 153	93 of 147	300	NCT00803738	Trial comparisons

Papers from its trials13

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42947086	DERIVED	1	PubMed
42464124	DERIVED	1	PubMed
41845293	DERIVED	1	PubMed
39979898	DERIVED	1	PubMed
38319878	DERIVED	2	PubMed
37640455	DERIVED	1	PubMed
36396498	DERIVED	5	PubMed
36255448	DERIVED	1	PubMed
35699443	DERIVED	1	PubMed
32818963	DERIVED	1	PubMed

1 to 10 of 13

See all 13 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006014

GET https://conductscience.org/api/diseases/v1/MONDO_0006014/drugs?page=2

API reference For AI assistants